tiprankstipranks
MEDICLIN AG (DE:MED)
XETRA:MED
Want to see DE:MED full AI Analyst Report?

MEDICLIN (MED) AI Stock Analysis

1 Followers

Top Page

DE:MED

MEDICLIN

(XETRA:MED)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 5.2)
Rating:63Neutral
Price Target:
€4.00
▲(11.11% Upside)
Action:Reiterated
Date:05/22/26
The score is driven primarily by improving financial performance and solid cash generation, tempered by balance-sheet risk from elevated leverage and a history of margin volatility. Technicals are mildly supportive with neutral momentum, and valuation looks reasonable at a ~12x P/E with a modest dividend.
Positive Factors
Revenue growth and improving operating performance
Sustained TTM revenue growth (up ~26%) with positive EBIT and net margins indicates expanding utilization and service uptake across clinics. This durable top-line improvement supports scale economics, covers fixed costs, and underpins sustainable operating cash flow and reinvestment capacity.
Negative Factors
Elevated leverage
A debt-to-equity ratio near 1.46x leaves the capital structure relatively heavy and reduces financial flexibility. High leverage increases interest and refinancing risk, constrains capacity for M&A or capex, and makes the firm more vulnerable to earnings volatility or adverse funding conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and improving operating performance
Sustained TTM revenue growth (up ~26%) with positive EBIT and net margins indicates expanding utilization and service uptake across clinics. This durable top-line improvement supports scale economics, covers fixed costs, and underpins sustainable operating cash flow and reinvestment capacity.
Read all positive factors

MEDICLIN (MED) vs. iShares MSCI Germany ETF (EWG)

MEDICLIN Business Overview & Revenue Model

Company Description
MEDICLIN Aktiengesellschaft operates hospitals in Germany. The company operates through Post-Acute, Acute, and Other Activities segments. It offers medical services in the areas of neurology, psychosomatics, orthopaedics, internal medicine, cardio...
How the Company Makes Money
MEDICLIN primarily makes money by operating healthcare facilities and billing for the medical services delivered at those sites. Key revenue streams include (1) inpatient acute-care treatment revenue generated when patients are admitted and treate...

MEDICLIN Financial Statement Overview

Summary
Operating performance is improving (TTM revenue up 26% with positive net and EBIT margins) and cash generation is healthy, but leverage remains a key constraint (debt-to-equity ~1.46x) and profitability/margins have been historically volatile.
Income Statement
68
Positive
Balance Sheet
52
Neutral
Cash Flow
63
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Dec 2021
Income Statement
Total Revenue786.53M784.49M748.80M730.10M704.70M673.10M
Gross Profit119.11M113.81M623.00M594.60M571.90M551.00M
EBITDA42.54M98.66M106.41M101.27M91.80M85.43M
Net Income29.18M25.49M24.84M-10.78M9.44M1.46M
Balance Sheet
Total Assets835.90M879.69M905.91M880.50M916.11M881.24M
Cash, Cash Equivalents and Short-Term Investments152.40M72.18M107.56M115.29M88.04M133.48M
Total Debt369.54M390.83M464.13M479.82M502.67M439.96M
Total Liabilities582.73M630.06M683.17M684.47M706.79M698.22M
Stockholders Equity252.47M248.95M222.51M195.92M209.21M183.28M
Cash Flow
Free Cash Flow48.68M51.44M35.88M40.43M8.62M64.96M
Operating Cash Flow93.98M99.87M80.57M78.00M34.64M81.97M
Investing Cash Flow-23.66M-37.14M-15.13M-9.51M-6.24M-7.09M
Financing Cash Flow-96.37M-97.40M-73.16M-45.48M-56.17M-55.26M

MEDICLIN Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.60
Price Trends
50DMA
3.51
Positive
100DMA
3.65
Negative
200DMA
3.49
Positive
Market Momentum
MACD
0.02
Negative
RSI
55.15
Neutral
STOCH
50.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Positive. The current price of 3.6 is above the 20-day moving average (MA) of 3.53, above the 50-day MA of 3.51, and above the 200-day MA of 3.49, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.15 is Neutral, neither overbought nor oversold. The STOCH value of 50.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MED.

MEDICLIN Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
83
Outperform
€353.39M6.0715.83%2.80%7.40%38.17%
74
Outperform
€151.50M11.0724.05%33.49%81.79%
63
Neutral
€171.00M12.0710.71%1.12%5.13%11.89%
57
Neutral
€843.42M16.323.04%0.77%6.06%0.93%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
41
Neutral
€20.45M-0.4523.56%3.51%-5.66%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:MED
MEDICLIN
3.66
0.76
26.21%
DE:RHK
RHON-KLINIKUM AG
12.50
-0.20
-1.54%
DE:MAK
MATERNUS-Kliniken AG
1.01
-0.58
-36.44%
DE:LIK
Limes Schlosskliniken AG
520.00
208.00
66.67%
DE:JTH0
Gesundheitswelt Chiemgau AG
11.30
-0.78
-6.46%
DE:M12
M1 Kliniken AG
18.98
4.80
33.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 22, 2026